BioCentury | Mar 13, 2020
Management Tracks

Camerini steps down as Cosmo CSO; plus CytoDyn, G1 Therapeutics, Flexion and Clearside

...Gastrointestinal disorders company Cosmo Pharmaceuticals N.V. (SIX:COPN) said CSO Roberto Camerini has resigned. Luigi Moro, who was Cosmo's...
...after serving as interim CEO. Targets CCR5 (CD195) - CC chemokine receptor 5 Robin Sawka, BioCentury Staff Cosmo Pharmaceuticals N.V. CytoDyn...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...Ltd. (Tokyo:4502; NYSE:TAK), and Walther was general manager at the Aries Pharmaceuticals Inc. subsidiary of Cosmo Pharmaceuticals N.V....
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...the Genentech Inc. unit of Roche, the Crucell N.V. unit of Johnson & Johnson and Cosmo Pharmaceuticals N.V....
...Therapeutics B.V., Amsterdam, Netherlands AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Atreca Inc., Redwood City, Calif. Cosmo Pharmaceuticals N.V....
BioCentury | Jan 12, 2019
Finance

We all fall down

...treat neutropenia and prevent febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs Cosmo Pharmaceuticals N.V....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...CSE:ORPHA) Arimoclomol Niemann-Pick disease type C Phase II/III final data 1Q19 Paion AG (Xetra:PA8) / Cosmo Pharmaceuticals N.V....
...α-mannosidosis EU NA Clovis Oncology Inc. (NASDAQ:CLVS) Rubraca rucaparib Ovarian cancer EU U.S. in 2016 Cosmo Pharmaceuticals N.V....
BioCentury | Nov 30, 2018
Clinical News

FDA approves traveler's diarrhea drug from Cosmo

...FDA approved Aemcolo rifamycin from Cosmo Pharmaceuticals N.V. (SIX:COPN) to treat travelers' diarrhea caused by non-invasive strains of...
...product has Qualified Infectious Disease Product (QIDP) designation from FDA and was under Priority Review. Cosmo Pharmaceuticals N.V....
...SIX:COPN), Dublin, Ireland Product: Aemcolo rifamycin Business: Gastrointestinal Elizabeth S. Eaton Aemcolo, Rifamycin SV, Rifamycin SV MMX (CB-01-11) Cosmo Pharmaceuticals N.V....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs PDUFA date 11/3/18 Cosmo Pharmaceuticals N.V....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...data October Coherus BioSciences Inc. (NASDAQ:CHRS) Biosimilar pegfilgrastim (CHS-1701) Neutropenia BsUFA; CHMP opinion 11/03/18; 2H18 Cosmo Pharmaceuticals N.V....
BioCentury | May 25, 2018
Clinical News

FDA accepts NDA for Cosmo's antibiotic

...Multi-Matrix system (MMX) technology. The product has Qualified Infectious Disease Product (QIDP) designation from FDA. Cosmo Pharmaceuticals N.V....
...Dublin, Ireland Product: Rifamycin SV MMX (CB-01-11) Business: Gastrointestinal Sandi Wong Aemcolo, Rifamycin SV, Rifamycin SV MMX (CB-01-11) Cosmo Pharmaceuticals N.V....
BioCentury | May 18, 2018
Company News

FDA accepts NDA for Cosmo's antibiotic

...FDA. Cosmo was up CHF7.30 to CHF126.90 on Friday. Sandi Wong Aemcolo, Rifamycin SV, Rifamycin SV MMX (CB-01-11) Cosmo Pharmaceuticals N.V....
Items per page:
1 - 10 of 166
BioCentury | Mar 13, 2020
Management Tracks

Camerini steps down as Cosmo CSO; plus CytoDyn, G1 Therapeutics, Flexion and Clearside

...Gastrointestinal disorders company Cosmo Pharmaceuticals N.V. (SIX:COPN) said CSO Roberto Camerini has resigned. Luigi Moro, who was Cosmo's...
...after serving as interim CEO. Targets CCR5 (CD195) - CC chemokine receptor 5 Robin Sawka, BioCentury Staff Cosmo Pharmaceuticals N.V. CytoDyn...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...Ltd. (Tokyo:4502; NYSE:TAK), and Walther was general manager at the Aries Pharmaceuticals Inc. subsidiary of Cosmo Pharmaceuticals N.V....
BioCentury | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

...the Genentech Inc. unit of Roche, the Crucell N.V. unit of Johnson & Johnson and Cosmo Pharmaceuticals N.V....
...Therapeutics B.V., Amsterdam, Netherlands AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Atreca Inc., Redwood City, Calif. Cosmo Pharmaceuticals N.V....
BioCentury | Jan 12, 2019
Finance

We all fall down

...treat neutropenia and prevent febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs Cosmo Pharmaceuticals N.V....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...CSE:ORPHA) Arimoclomol Niemann-Pick disease type C Phase II/III final data 1Q19 Paion AG (Xetra:PA8) / Cosmo Pharmaceuticals N.V....
...α-mannosidosis EU NA Clovis Oncology Inc. (NASDAQ:CLVS) Rubraca rucaparib Ovarian cancer EU U.S. in 2016 Cosmo Pharmaceuticals N.V....
BioCentury | Nov 30, 2018
Clinical News

FDA approves traveler's diarrhea drug from Cosmo

...FDA approved Aemcolo rifamycin from Cosmo Pharmaceuticals N.V. (SIX:COPN) to treat travelers' diarrhea caused by non-invasive strains of...
...product has Qualified Infectious Disease Product (QIDP) designation from FDA and was under Priority Review. Cosmo Pharmaceuticals N.V....
...SIX:COPN), Dublin, Ireland Product: Aemcolo rifamycin Business: Gastrointestinal Elizabeth S. Eaton Aemcolo, Rifamycin SV, Rifamycin SV MMX (CB-01-11) Cosmo Pharmaceuticals N.V....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs PDUFA date 11/3/18 Cosmo Pharmaceuticals N.V....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...data October Coherus BioSciences Inc. (NASDAQ:CHRS) Biosimilar pegfilgrastim (CHS-1701) Neutropenia BsUFA; CHMP opinion 11/03/18; 2H18 Cosmo Pharmaceuticals N.V....
BioCentury | May 25, 2018
Clinical News

FDA accepts NDA for Cosmo's antibiotic

...Multi-Matrix system (MMX) technology. The product has Qualified Infectious Disease Product (QIDP) designation from FDA. Cosmo Pharmaceuticals N.V....
...Dublin, Ireland Product: Rifamycin SV MMX (CB-01-11) Business: Gastrointestinal Sandi Wong Aemcolo, Rifamycin SV, Rifamycin SV MMX (CB-01-11) Cosmo Pharmaceuticals N.V....
BioCentury | May 18, 2018
Company News

FDA accepts NDA for Cosmo's antibiotic

...FDA. Cosmo was up CHF7.30 to CHF126.90 on Friday. Sandi Wong Aemcolo, Rifamycin SV, Rifamycin SV MMX (CB-01-11) Cosmo Pharmaceuticals N.V....
Items per page:
1 - 10 of 166